Income statement, balance sheet and cash flow statement for the last 1 fiscal years, taken from the XBRL data Revium Rx. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
Income tax
0.36
Net income
-13.4
EPS, basic
-0.22
EPS, diluted
-0.22
Shares, basic (weighted)
60.7
Shares, diluted (weighted)
60.7
Balance sheet
FY2025
Cash and equivalents
1.68
Other current assets
0.38
Total current assets
3.1
Property, plant and equipment
0.01
Lease right-of-use assets
0.12
Goodwill
2.58
Intangible assets
2.5
Total assets
8.3
Accounts payable
0.16
Accrued liabilities
0.46
Total current liabilities
0.8
Lease liabilities
0.05
Total liabilities
1.42
Paid-in capital
31.8
Retained earnings
-25
Shareholders' equity
6.88
Total equity
6.88
Total liabilities and equity
8.3
Shares outstanding
60.7
Cash flow statement
FY2025
Net income
-13.4
Stock-based compensation
0.62
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $1.43 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-195.5%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-162.0%
Net income / average total assets.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.87x
Current assets / current liabilities.
Quick ratio
2.10x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.10x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.22
Net income per basic share, as reported (split-adjusted).
Book value per share
$0.11
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
12.6x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
48.0x
Market cap / tangible book value, when positive.
Earnings yield
-15.5%
Net income / market cap (the inverse of P/E).
Was Revium Rx. profitable in fiscal 2025?
No. It reported a net loss of $13.4M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.